Herbert L. Bonkovsky

Active 1985–2025

151
Papers
26,637
Citations
96
h-index
145
i10-index

Citations

Citations per year for Herbert L. Bonkovsky1985: 1 citations1986: 5 citations1987: 3 citations1988: 5 citations1989: 3 citations1990: 5 citations1991: 4 citations1992: 9 citations1993: 9 citations1994: 18 citations1995: 22 citations1996: 12 citations1997: 32 citations1998: 30 citations1999: 50 citations2000: 85 citations2001: 89 citations2002: 128 citations2003: 96 citations2004: 72 citations2005: 80 citations2006: 126 citations2007: 111 citations2008: 103 citations2009: 111 citations2010: 172 citations2011: 195 citations2012: 212 citations2013: 177 citations2014: 255 citations2015: 284 citations2016: 249 citations2017: 225 citations2018: 150 citations2019: 818 citations2020: 707 citations2021: 796 citations2022: 661 citations2023: 395 citations2024: 695 citations2025: 272 citations2026: 6 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,312 citing papers, 28.6% of this breakdownChina: 777 citing papers, 9.6% of this breakdownGermany: 475 citing papers, 5.9% of this breakdownUnited Kingdom: 471 citing papers, 5.8% of this breakdownItaly: 385 citing papers, 4.8% of this breakdownSpain: 336 citing papers, 4.2% of this breakdownFrance: 322 citing papers, 4% of this breakdownJapan: 257 citing papers, 3.2% of this breakdownCanada: 242 citing papers, 3% of this breakdownAustralia: 176 citing papers, 2.2% of this breakdownIndia: 171 citing papers, 2.1% of this breakdownSwitzerland: 145 citing papers, 1.8% of this breakdown
0%28.6%Other 24.8%

Fields

  • Medicine51.8%
  • Biochemistry, Genetics and Molecular Biology28.2%
  • Pharmacology, Toxicology and Pharmaceutics12.8%
  • Immunology and Microbiology2.1%
  • Agricultural and Biological Sciences1%
  • Nursing0.8%
  • Other3.3%

Topics

  • Liver Disease Diagnosis and Treatment9.1%
  • Drug-Induced Hepatotoxicity and Protection5.4%
  • Hepatitis C virus research4.9%
  • Liver Disease and Transplantation3.7%
  • Hepatitis B Virus Studies2.6%
  • Hepatocellular Carcinoma Treatment and Prognosis2.6%
  • Other71.7%

Coauthors

All papers

Open in search
  1. Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Akshay Vaishnaw, Jae Bum Kim, Amy Simon, Laurent Gouya - New England Journal of Medicine 2020 cited by 592

  2. Features and Outcomes of 899 Patients With Drug-Induced Liver Injury: The DILIN Prospective Study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Marwan Ghabril, David S. Goldstein, Vani Gopalreddy, Priya Grewal, Paul H. Hayashi, Jay H. Hoofnagle, Neil Kaplowitz, Suthat Liangpunsakul, Steven N. Lichtman, Lawrence Liu, Victor J. Navarro, Joseph A. Odin, Simona Rossi, Mark W. Russo, Thomas D. Schiano, José Serrano, Averell H. Sherker, Andrew Stolz, Raj Vuppalanchi, Paul B. Watkins, Steven Zacks, Amanda Balasco, Kristin Chesney, Audrey Corne, Sherrie Cummings, Gale Groseclose, Alex Hammett, Judy Hooker, Varun Kesar, Sophana Mao, Kenari Marks, R. Bruce McFadden, Yolanda Melgoza, Sherif Mikhail, Susan L Milstein, Wendy Morlan, Val Peacock, Nidia Rosado, Tracy Russell, Maricruz Vega, Manisha Verma, Patricia Walker, Rachana Yalamanchili, Michelle McClanahan-Crowder, Katherine Galan, Jiezhun Gu, Tuan Chau, Kowsalya Ragavan, Hoss Rostami, Carmel Puglisi-Scharenbroich, Rebecca Torrance, Rebekah Van Raaphorst - Gastroenterology 2015 cited by 899

  3. ACG Clinical Guideline: The Diagnosis and Management of Idiosyncratic Drug-Induced Liver Injury

    Authors: , , , , , - The American Journal of Gastroenterology 2014 cited by 865

  4. Drug-Induced Liver Injury Network (DILIN) Prospective Study

    Authors: , , , , , , - Drug Safety 2009 cited by 486

  5. Hepatic Histological Findings in Suspected Drug-Induced Liver Injury: Systematic Evaluation and Clinical Associations

    Authors: , , , , , , , , , , , , , , - Hepatology 2013 cited by 417

  6. Recent insights into the biological functions of liver fatty acid binding protein 1

    Authors: , , , - Journal of Lipid Research 2015 cited by 267

  7. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - Nature Genetics 2013 cited by 922

  8. Causes, Clinical Features, and Outcomes From a Prospective Study of Drug-Induced Liver Injury in the United States

    Authors: , , , , , , , - Gastroenterology 2008 cited by 896

  9. Liver Injury Associated with Turmeric—A Growing Problem: Ten Cases from the Drug-Induced Liver Injury Network [DILIN]

    Authors: , , , , , , , , , , , , , , - The American Journal of Medicine 2022 cited by 94

  10. Porphyria

    Authors: , , - New England Journal of Medicine 2017 cited by 391

  11. Vascular Endothelium As a Contributor of Plasma Sphingosine 1-Phosphate

    Authors: , , , , , , , , - Circulation Research 2008 cited by 475

  12. Candidate biomarkers for the diagnosis and prognosis of drug‐induced liver injury: An international collaborative effort

    Authors: , , , , , , , , , , , , , , , , , , , , , , - Hepatology 2018 cited by 243

  13. Complication Rate of Percutaneous Liver Biopsies Among Persons With Advanced Chronic Liver Disease in the HALT-C Trial

    Authors: , , , , , , , , , , - Clinical Gastroenterology and Hepatology 2010 cited by 466

  14. Phase 1 Trial of an RNA Interference Therapy for Acute Intermittent Porphyria

    Authors: , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2019 cited by 257

  15. Des-γ-Carboxy Prothrombin and α-Fetoprotein as Biomarkers for the Early Detection of Hepatocellular Carcinoma

    Authors: , , , , , , , , , , - Gastroenterology 2009 cited by 559

  16. HLA‐B*35:01 and Green Tea–Induced Liver Injury

    Authors: , , , , , , , , , , , , , , , , , , , - Hepatology 2020 cited by 94

  17. Efficacy and safety of givosiran for acute hepatic porphyria: 24‐month interim analysis of the randomized phase 3 ENVISION study

    Authors: , , , , , , , , , , , , , , , , , - Liver International 2021 cited by 77

  18. Afamelanotide for Erythropoietic Protoporphyria

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2015 cited by 279

  19. Liver injury from herbals and dietary supplements in the U.S. Drug-Induced Liver Injury Network

    Authors: , , , , , , , , , , , , , - Hepatology 2014 cited by 416

  20. United States Pharmacopeia (USP) comprehensive review of the hepatotoxicity of green tea extracts

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - Toxicology Reports 2020 cited by 159

  21. Clinical presentations and outcomes of bile duct loss caused by drugs and herbal and dietary supplements

    Authors: , , , , , , , , , , - Hepatology 2016 cited by 147

  22. Spectrum of statin hepatotoxicity: Experience of the drug-induced liver injury network

    Authors: , , , , , , , - Hepatology 2014 cited by 240

  23. Comparison of Aliasing Errors for Primitive and Non-Primitive Polynomials

    Authors: , , , , , , , , , , , , , , , , , , - Clinical Gastroenterology and Hepatology 1986 cited by 61

  24. Efficacy and safety of givosiran for acute hepatic porphyria: Final results of the randomized phase III ENVISION trial

    Authors: , , , , , , , , , , , - Journal of Hepatology 2023 cited by 48